Advances in Proteomic and Metabolomic Profiling of Neurodegenerative Diseases

Overview

Journal Front Neurol

Specialty Neurology

Date 2022 Feb 17

PMID 35173667

Authors

Artur Schumacher-Schuh

Andrei Bieger

Wyllians V Borelli

Makayla K Portley

Paula Saffie Awad

Sara Bandres-Ciga

Affiliations

Soon will be listed here.

Abstract

Proteomics and metabolomics are two emerging fields that hold promise to shine light on the molecular mechanisms causing neurodegenerative diseases. Research in this area may reveal and quantify specific metabolites and proteins that can be targeted by therapeutic interventions intended at halting or reversing the neurodegenerative process. This review aims at providing a general overview on the current status of proteomic and metabolomic profiling in neurodegenerative diseases. We focus on the most common neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis. We discuss the relevance of state-of-the-art metabolomics and proteomics approaches and their potential for biomarker discovery. We critically review advancements made so far, highlighting how metabolomics and proteomics may have a significant impact in future therapeutic and biomarker development. Finally, we further outline technologies used so far as well as challenges and limitations, placing the current information in a future-facing context.

Citing Articles

Advances in Huntington's Disease Biomarkers: A 10-Year Bibliometric Analysis and a Comprehensive Review.

Aqel S, Ahmad J, Saleh I, Fathima A, Al Thani A, Mohamed W Biology (Basel). 2025; 14(2).

PMID: 40001897 PMC: 11852324. DOI: 10.3390/biology14020129.

Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives.

Molla G, Bitew M Biomedicines. 2025; 12(12.

PMID: 39767657 PMC: 11673561. DOI: 10.3390/biomedicines12122750.

Scrutinizing neurodegenerative diseases: decoding the complex genetic architectures through a multi-omics lens.

Cocos R, Popescu B Hum Genomics. 2024; 18(1):141.

PMID: 39736681 PMC: 11687004. DOI: 10.1186/s40246-024-00704-7.

Decoding Neurodegeneration: A Review of Molecular Mechanisms and Therapeutic Advances in Alzheimer's, Parkinson's, and ALS.

Toader C, Tataru C, Munteanu O, Serban M, Covache-Busuioc R, Ciurea A Int J Mol Sci. 2024; 25(23.

PMID: 39684324 PMC: 11641752. DOI: 10.3390/ijms252312613.

Biomarker Methodologies: A NIMH Perspective.

Grabb M, Brady L Adv Neurobiol. 2024; 40:3-44.

PMID: 39562439 DOI: 10.1007/978-3-031-69491-2_1.

References

Blasco H, Veyrat-Durebex C, Bocca C, Patin F, Vourch P, Kouassi Nzoughet J . Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Sci Rep. 2017; 7(1):17652. PMC: 5732162. DOI: 10.1038/s41598-017-17389-9. View

Crotty G, Maciuca R, Macklin E, Wang J, Montalban M, Davis S . Association of caffeine and related analytes with resistance to Parkinson disease among mutation carriers: A metabolomic study. Neurology. 2020; 95(24):e3428-e3437. PMC: 7836665. DOI: 10.1212/WNL.0000000000010863. View

Kumari S, Kumaran S, Goyal V, Sharma R, Sinha N, Dwivedi S . Identification of potential urine biomarkers in idiopathic parkinson's disease using NMR. Clin Chim Acta. 2020; 510:442-449. DOI: 10.1016/j.cca.2020.08.005. View

Ashton N, Nevado-Holgado A, Barber I, Lynham S, Gupta V, Chatterjee P . A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. Sci Adv. 2019; 5(2):eaau7220. PMC: 6365111. DOI: 10.1126/sciadv.aau7220. View

Li X, An W, Alafuzoff I, Soininen H, Winblad B, Pei J . Phosphorylated eukaryotic translation factor 4E is elevated in Alzheimer brain. Neuroreport. 2004; 15(14):2237-40. DOI: 10.1097/00001756-200410050-00019. View

Jiang R, Rong C, Ke R, Meng S, Yan X, Ke H . Differential proteomic analysis of serum exosomes reveals alterations in progression of Parkinson disease. Medicine (Baltimore). 2019; 98(41):e17478. PMC: 6799836. DOI: 10.1097/MD.0000000000017478. View

Baloni P, Funk C, Yan J, Yurkovich J, Kueider-Paisley A, Nho K . Metabolic Network Analysis Reveals Altered Bile Acid Synthesis and Metabolism in Alzheimer's Disease. Cell Rep Med. 2020; 1(8):100138. PMC: 7691449. DOI: 10.1016/j.xcrm.2020.100138. View

DAndrea G, Pizzolato G, Gucciardi A, Stocchero M, Giordano G, Baraldi E . Different Circulating Trace Amine Profiles in De Novo and Treated Parkinson's Disease Patients. Sci Rep. 2019; 9(1):6151. PMC: 6467876. DOI: 10.1038/s41598-019-42535-w. View

Ichi I, Nakahara K, Miyashita Y, Hidaka A, Kutsukake S, Inoue K . Association of ceramides in human plasma with risk factors of atherosclerosis. Lipids. 2006; 41(9):859-63. DOI: 10.1007/s11745-006-5041-6. View

10.

Jack Jr C, Bennett D, Blennow K, Carrillo M, Dunn B, Budd Haeberlein S . NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018; 14(4):535-562. PMC: 5958625. DOI: 10.1016/j.jalz.2018.02.018. View

11.

Goutman S, Boss J, Guo K, Alakwaa F, Patterson A, Kim S . Untargeted metabolomics yields insight into ALS disease mechanisms. J Neurol Neurosurg Psychiatry. 2020; 91(12):1329-1338. PMC: 7677469. DOI: 10.1136/jnnp-2020-323611. View

12.

Garcia-Ruiz C, Morales A, Fernandez-Checa J . Glycosphingolipids and cell death: one aim, many ways. Apoptosis. 2015; 20(5):607-20. PMC: 4691703. DOI: 10.1007/s10495-015-1092-6. View

13.

Barthelemy N, Horie K, Sato C, Bateman R . Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med. 2020; 217(11). PMC: 7596823. DOI: 10.1084/jem.20200861. View

14.

Montagne A, Barnes S, Sweeney M, Halliday M, Sagare A, Zhao Z . Blood-brain barrier breakdown in the aging human hippocampus. Neuron. 2015; 85(2):296-302. PMC: 4350773. DOI: 10.1016/j.neuron.2014.12.032. View

15.

Mentis A, Dardiotis E, Efthymiou V, Chrousos G . Non-genetic risk and protective factors and biomarkers for neurological disorders: a meta-umbrella systematic review of umbrella reviews. BMC Med. 2021; 19(1):6. PMC: 7805241. DOI: 10.1186/s12916-020-01873-7. View

16.

Verde F, Steinacker P, Weishaupt J, Kassubek J, Oeckl P, Halbgebauer S . Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2018; 90(2):157-164. DOI: 10.1136/jnnp-2018-318704. View

17.

Genoud S, Senior A, Hare D, Double K . Meta-Analysis of Copper and Iron in Parkinson's Disease Brain and Biofluids. Mov Disord. 2020; 35(4):662-671. DOI: 10.1002/mds.27947. View

18.

Lanznaster D, Veyrat-Durebex C, Vourch P, Andres C, Blasco H, Corcia P . Metabolomics: A Tool to Understand the Impact of Genetic Mutations in Amyotrophic Lateral Sclerosis. Genes (Basel). 2020; 11(5). PMC: 7288444. DOI: 10.3390/genes11050537. View

19.

Yu Z, Zhang S, Wang D, Fan M, Gao F, Sun W . The significance of uric acid in the diagnosis and treatment of Parkinson disease: An updated systemic review. Medicine (Baltimore). 2017; 96(45):e8502. PMC: 5690738. DOI: 10.1097/MD.0000000000008502. View

20.

Pedrero-Prieto C, Garcia-Carpintero S, Frontinan-Rubio J, Llanos-Gonzalez E, Aguilera Garcia C, Alcain F . A comprehensive systematic review of CSF proteins and peptides that define Alzheimer's disease. Clin Proteomics. 2020; 17:21. PMC: 7273668. DOI: 10.1186/s12014-020-09276-9. View